Search

Omacetaxine mepesuccinate

Then in March 2006, it received Orphan Drug status from the FDA for the treatment of CML. … In November 2006, omacetaxine mepesuccinate, for the treatment of CML, was granted Fast Track designation by the FDA.

Albumin Aggregated

Albumin aggregated is an ingredient in the DRAXIMAGE MAA kit for the preparation of technetium tc99m albumin aggregated injection.

Hydroxyproline

Therapeutically, hydroxyproline is being studied as an an experimental medicine but is approved in France as a combination topical gel product called Cicactive for small, superficial wounds. … It is found in collagen and as such it is common in many gelatin products. Hydroxyproline is mostly used as a diagnostic marker of bone turnover and liver fibrosis.

Sitaxentan

In 2010, Pfizer voluntarily removed sitaxentan from the market over concerns of hepatotoxicity. … Sitaxentan was marketed under the trade name Thelin for the treatment of pulmonary arterial hypertension (PAH) by Encysive Pharmaceuticals until Pfizer purchased Encysive in February 2008.

LS11

LS11(talaporfin sodium) is an agent consisting of chlorin e6, derived from chlorophyll, and L-aspartic acid with photosensitizing activity. … After intratumoral activation by light emitting diodes, taporfin sodium forms an extended high energy conformational state that generates singlet oxygen, resulting in free radical-mediated cell death.

Rabies immune globulin, human

Committee on Immunization Practices (ACIP), and the World Health Organization (WHO). … Recommendations for passive and/or active immunization after exposure to an animal suspected of having rabies have been outlined by the National Advisory Committee on Immunization (NACI), the Advisory

Malathion

Malathion is an irreversible cholinesterase inhibitor and has low human toxicity. … Malathion is a parasympathomimetic organophosphate compound that is used as an insecticide for the treatment of head lice.

Calcium alginate

PEG-uricase

of severe, treatment-refractory gout in the United States in 2006. … PEG-uricase, a polyethylene glycol ("PEG") conjugate of recombinant porcine uricase (urate oxidase), which breaks down the uric acid deposits is being studied in Phase III clinical trials for the treatment

Deutivacaftor

[L52275,A179677] Deutivacaftor was first approved by the US FDA in December 2024 in combination with two CFTR correctors - [tezacaftor] and [vanzacaftor] - for the treatment of patients with responsive … It is used alongside CFTR correctors to increase the quantity and function of CFTR at the cell surface in patients with cystic fibrosis.